Article PDF
Avoid common mistakes on your manuscript.
References
Rouse R, Kruhlak N, Weaver J, et al. Translating new science into the drug review process: the US FDA’s Division of Applied Regulatory Science. Therapeutic Innovation & Regulatory Science. 2018;52:244–255.
Tan-Koi WC, Leow PC, Teo YY. Applications of pharmacogenomics in regulatory science: a product life cycle review. Pharmacogenomics J. 2018;18:359–366.
International Council for Harmonisation of Technical Requirements of Pharmaceuticals for Human Use. www.ich.org (accessed July 7, 2019).
ICH press release. file:///C:/Users/owner/AppData/Local/Microsoft/Windows/INetCache/IE/JDC9IEBW/ICH38Amsterdam_PressRelease_2019_0614_Final.pdf (accessed July 7, 2019).
Törnqvist E, Annas A, Granath B, et al. Strategic focus on 3 R principles reveals major reductions in the use of animals in pharmaceutical toxicity testing. PLoS One. 2014;9:e101638.
Aske KC, Waugh CA. Expanding the 3 R principles: more rigour and transparency in research using animals. EMBO Rep. 2017;18: 1490–1492.
Franco NH, Sandøe P, Olsson IAS. Researchers’ attitudes to the 3Rs—an upturned hierarchy? PLoS One. 2018;13(8):e0200895.
Satin LZ, Durham TA, Turner JR. Assessing a drug’s proarrhythmic liability: an overview of computer simulation modeling, non-clinical assays, and the Thorough QT/QTc Study. Drug Info J. 2011:45;357–375.
Turner JR, Karnad DR, Cabell CH, Kothari S. Recent developments in the science of proarrhythmic cardiac safety of new drugs. Eur Heart J Cardiovasc Pharmacother. 2017;3:118–124.
Turner JR, Rodriquez I, Mantovani E, et al; on behalf of the Cardiac Safety Research Consortium. Drug-induced proarrhythmia and torsade de pointes: a primer for students and practitioners of medicine and pharmacy. J Clin Pharmacol. 2018; 58:997–1012.
Vicente J, Strauss DG, Upreti VV, et al. The potential role of the J-Tpeak interval in proarrhythmic cardiac safety: current state of the science from the American College of Clinical Pharmacology and the Cardiac Safety Research Consortium. J Clin Pharmacol. 2019;59:909–914.
Vlachos K, Georgopoulos S, Efremidis M, Sideris A, Letsas KP. An update on risk factors for drug-induced arrhythmias. Expert Rev Clin Pharmacol. 2016;9:117–127.
Vandael E, Vandenberk B, Vandenberghe J, Willems R, Foulon V. Risk factors for QTc-prolongation: systematic review of the evidence. Int J Clin Pharm. 2017;39:16–25.
Heemskerk CPM, Pereboom M, van Stralen K, et al. Risk factors for QTc interval prolongation. Eur J Clin Pharmacol. 2018;74: 183–191.
Link MG, Yan GX, Kowey PR. Evaluation of toxicity for heart failure therapeutics: studying effects on the QT interval. Circ Heart Fail. 2010;3:547–555.
ICH S7B. The non-clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. file:///C:/Users/owner/AppData/Local/Microsoft/Windows/INetCache/IE/JDC9IEBW/S7B_Guideline.pdf (accessed July 7, 2019).
ICH E14. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for nonantiarrhythmic drugs. file:///C:/Users/owner/AppData/Local/Microsoft/Windows/INetCache/IE/2VUBCJEZ/E14_Guideline.pdf (accessed July 7, 2019).
E14 Implementation Working Group ICH E14 Guideline: The clinical evaluation of QT/QTc interval prolongation and proar-rhythmic potential for non-antiarrhythmic drugs: questions & answers (R3). file:///C:/Users/owner/AppData/Local/Microsoft/Windows/INetCache/IE/0GZPBQG6/E14_Q_As_R3__Step4.pdf (accessed July 7, 2019).
ICH. Concept paper. file:///C:/Users/owner/AppData/Local/Microsoft/Windows/INetCache/IE/JDC9IEBW/E14S7BIWG_ConceptPaper_Final_2018_1122.pdf (accessed July 7, 2019).
ICH E14/S7B IWG work plan. file:///C:/Users/owner/AppData/Local/Microsoft/Windows/INetCache/IE/QILS3H1V/E14-S7B_IWG_WorkPlan_2019_0220.pdf (accessed July 7, 2019).
ICH E14/S7B IWG membership list. file:///C:/Users/owner/AppData/Local/Microsoft/Windows/INetCache/IE/2VUBCJEZ/E14-S7B_IWG_ExpertsList_2019_0208.pdf (accessed July 7, 2019).
Sager PT, Gintant G, Turner JR, Pettit S, Stockbridge N. Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report from the Cardiac Safety Research Consortium. Am Heart J. 2014;167:292–300.
Gintant G, Sager PT, Stockbridge N. Evolution of strategies to improve preclinical cardiac safety testing. Nat Rev Drug Discov. 2016;15:457–471.
Vicente J, Zusterzeel R, Johannesen L, et al. Mechanistic model-informed proarrhythmic risk assessment of drugs: review of the “CiPA” Initiative and design of a prospective clinical validation study. Clin Pharmacol Ther. 2018;103:54–66.
Wallis R, Benson C, Darpo B, et al. CiPA challenges and opportunities from a non-clinical, clinical and regulatory perspectives. An overview of the safety pharmacology scientific discussion. J Pharmacol Toxicol Methods. 2018;93:15–25.
Vicente J. Update on the ECG component of the CiPA initiative. J Electrocardiol. 2018;51(6 suppl): S98–S102.
Rights and permissions
About this article
Cite this article
Turner, J.R. The International Council for Harmonisation and a Case Study in Regulatory Science. Ther Innov Regul Sci 53, 561–563 (2019). https://doi.org/10.1177/2168479019869740
Published:
Issue Date:
DOI: https://doi.org/10.1177/2168479019869740